Nynomic (M7U) H1 2025 earnings summary

Executive summary

• Revenue declined 12% year-over-year to EUR 42.1 million in H1 2025 due to weak global demand, project delays, and customer caution in a challenging macroeconomic environment.

• EBIT dropped to EUR -2.0 million, impacted by restructuring costs from the NyFIT2025 efficiency program, with an EBIT margin of -5%.

• Order backlog remains robust at EUR 43.4 million, though down 9% from year-end 2024.

• No major project cancellations or product discontinuations; customer interest remains high.

Financial highlights

• EBITDA fell 88% year-over-year to EUR 0.8 million.

• EPS before minority interests was EUR -0.50 (vs. EUR 0.40 in H1 2024); after minorities, EUR -0.47.

• Operating cash flow was negative at EUR -1.3 million (vs. EUR 0.6 million in H1 2024).

• Investments totaled EUR 1.3 million, down 39% year-over-year.

• Equity ratio increased to 74.9% (from 73.8% at year-end 2024), reflecting a strong capital structure.

Outlook and guidance

• Full-year 2025 revenue forecast revised down to EUR 100–105 million (from EUR 105–110 million); EBIT expected at EUR 2–4 million (previously EUR 8.5–10 million).

• Management expects a stronger H2 2025, with significant improvement in Q4, but market uncertainty persists.

• Medium-term target remains annual revenue of at least EUR 200 million and EBIT margin of 16–19%.